Related Experiment Video
Updated: Jun 15, 2025

07:11
Isolation of Infiltrating Leukocytes from Mouse Skin Using Enzymatic Digest and Gradient Separation
Published on: January 25, 2016
21.3K
The causal relationship between immune cells and atopic dermatitis: A bidirectional Mendelian randomization study
1Department of dermatology, Shenzhen Second People's Hospital. The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Summary
This study reveals specific immune cell differences linked to atopic dermatitis (AD) risk. Certain immune cell elevations increase AD risk, while others, like CD4 T regulatory cells, appear protective.
Area of Science:
- Immunology
- Dermatology
- Genetics
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition with unclear origins.
- Epidemiological data suggest immune factors are crucial in AD development.
- Previous studies on immune inflammation and AD have produced conflicting results.
Purpose of the Study:
- To investigate the causal relationship between immunological features and AD risk.
- To utilize a bidirectional, two-sample Mendelian randomization approach.
- To analyze associations between 731 immunological cell features and AD.
Main Methods:
- Employed a bidirectional, two-sample Mendelian randomization (MR) design.
- Utilized large-scale, publicly available genome-wide association study data.
- Examined causal links between 731 immune cell phenotypes and AD susceptibility.
Main Results:
- Six immune phenotypes showed significant associations with AD risk.
- Increased Basophil %CD33dim HLA DR-CD66b-, CD25 on IgD+ CD24+, CD40 on monocytes, and HLA DR on monocytes correlated with higher AD risk.
- Elevated CD3 on CD4 Treg cells were associated with lower AD risk; reverse MR showed AD influencing B cell populations.
Conclusions:
- The study clarifies the complex relationship between specific immune cells and atopic dermatitis.
- Findings provide insights into AD pathophysiology.
- Results may guide future therapeutic strategies for AD.

